ADC Therapeutics SAADCT

ADC Therapeutics SA’s latest 10-Q reveals a company that can boast a $231 million cash cushion but must explain a $216.4 million deficit in shareholders’ equity, a $33.0 million net loss in Q1 2026, and $29.7 million of operating cash burn for the same quarter. Revenue from ZYNLONTA® totalled $20.0 million, barely enough to cover the $19.9 million R&D tab for the period, while capex amounted to a rounding error of $32,000. The balance sheet now shows $291.5 million in assets against $507.9 million in liabilities, a structure that will require either rapid sales growth or fresh financing to avoid further dilution.

ADC Therapeutics markets ZYNLONTA®, an FDA-approved anti-CD19 antibody-drug conjugate aimed at relapsed or refractory large B-cell lymphoma, and the company lists a full pipeline on its science pages. Yet the firm’s June 3 press release bluntly admits that LOTIS-5’s confirmatory Phase 3 trial has not yet delivered the data set regulators need, delaying any commercial upside. Completion of the LOTIS-7 Phase 1b combination study with rituximab is announced, but Phase 1b is not a revenue event; it is a data-gathering exercise. The June 24 press release trumpets a “strategic reorganization to support ZYNLONTA growth,” yet the same filing shows R&D spend of $19.9 million against near-zero capital investment, underscoring that growth here still means research, not expansion.

Operating income in Q1 clocked in at -$25.2 million, net loss at -$33.0 million, and EPS at -$0.21 on a diluted share count of 154.1 million. Inventory rose only $16,000 in the quarter to $4.8 million, suggesting either tight supply control or the absence of commercial momentum. The company’s cash and equivalents stand at $231 million, a figure that sounds robust until you notice it is shrinking by roughly $30 million per quarter. The board’s June reorganization promises to “support ZYNLONTA growth opportunities and regulatory priorities,” language that usually precedes either a pivotal approval or a capital call.

For readers tracking the stock via TradingView, the ticker ADCT is listed on the SIX Swiss Exchange under the Swiss Security Number 4220759; the share price is not part of this filing-based report. The chart rail on this page will display the daily candlestick series for ADCT in Swiss francs, but no price levels are asserted here. The market mechanism remains a secondary screen: the primary question is whether ZYNLONTA’s next data package is strong enough to unlock pricing power and justify the current burn.

What changed this quarter is that the company has acknowledged it still needs more regulatory clarity before any revenue acceleration can begin, while continuing to fund a pipeline that demands $19-20 million of R&D each quarter. What remains unproven is whether the LOTIS programme will deliver the confirmatory data regulators seek, or whether investors will fund further dilution while they wait. The evidence that would decisively change the file next is a positive read-out or conditional approval from FDA for a ZYNLONTA label expansion, or a term-sheet for fresh capital that materially extends the runway beyond the current cash burn profile.